BIIB Stock Analysis: Buy, Sell, or Hold?
BIIB - Biogen Inc. Common Stock
$209.03
9.88 (4.96%)
▲
5d:
+0.27%
30d:
+7.61%
90d:
+20.85%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 29, 2026
14d
Smart Money Distribution
None View Scanner →
Strength: 5.9/10
Get Alerted When BIIB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BIIB shows positive signals but monitor for confirmation. Market pricing in 2.6% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: BIIB shows positive signals but monitor for confirmation. Market pricing in 2.6% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$378.50
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$235.02
11.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BIIB is currently trading at $209.03, which is considered slightly high relative to its 30-day fair value range of $195.16 to $209.60. The stock's valuation (Forward PE: 12.6) is in line with its historical norms (11.7). At these levels, the market is pricing in 2.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BIIB is in a uptrend. Immediate support is located at $194.37, while resistance sits at $219.72. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BIIB is in a uptrend. Immediate support is located at $194.37, while resistance sits at $219.72. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$195.16 -
$209.60
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.2%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.0%)
- NEUTRAL: Near Wall St target ($222.83)
- NEUTRAL: Market pricing in 2.6% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$195.16 -
$209.60
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$194.37
Resistance Level
$219.72
Current Trend
Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.58
Wall Street Target
$222.83
(+6.6%)
Revenue Growth (YoY)
1.9%
Earnings Growth (YoY)
31.1%
Profit Margin
13.8%
Valuation Premium vs History
+2.6% premium
PE vs Historical
12.6 vs 11.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.6%
(market-implied from PE analysis)
1-Year Target
$214.46
(+3%)
2-Year Target
$220.04
(+5%)
3-Year Target
$225.76
(+8%)
3-Yr Target (if PE normalizes)
(PE: 13→12)
PE COMPRESSION
$209.92
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 27.2%)
$744.97
(+256%)
Base:
(SPY PE: 12.6, Growth: 27.2%)
$430.38
(+106%)
Bear:
(PE: 10.7, Growth: 27.2%)
$365.82
(+75%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 21.41 | Current EPS (TTM): $9.30
Bull Case
$391.31
(+87%)
Analyst growth 78.6%, PE expands to 23.6
Base Case
$355.74
(+70%)
Market implied 78.6%, PE stable at 21.4
Bear Case
$135.42
(-35%)
Severe decline -20.0%, PE contracts to 18.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 13, 2026 9:09 PM ET
Data refreshes hourly during market hours. Next update: 10:09 PM
Data refreshes hourly during market hours. Next update: 10:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIIB showing a specific setup today?
Insider Activity (6 Months)
3
Buys
3
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Nicole Murphy
BUY
3 shares
2026-02-12
Priya Singhal
SELL
2660 shares
2026-02-09
Ro Khanna
SELL
2026-02-06
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1240 | 58 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 64 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$263 | 59 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$356 | 56 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$132 | 59 HOLD |
Advanced BIIB Option Strategies
Professional options setups generated by AI based on today's BIIB price and gamma walls.
